Vistagen Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · South San Francisco, CA
VTGN chart
What traders are saying about $VTGN
Latest postsVistagen Therapeutics, Inc. news
- symbol__ Stock Quote Price and Forecast
CNN ·
- VistaGen Receives Constructive FDA Feedback on Fasedienol Phase 3 Planning
TipRanks ·
- Form 8K VistaGen Therapeutics Inc For: 9 November By Investing.com
Investing.com Canada ·
- After FDA feedback, Vistagen (VTGN) plans to study more than acute social anxiety relief.
Stock Titan ·
- Vistagen Provides Regulatory Update Following Productive Type C Meeting with U.S. FDA on Phase 3 Development of Fasedienol for Social Anxiety Disorder
Yahoo Finance ·
- FDA recommends tracking patient function over time in an anxiety-drug study
Stock Titan ·
- Vistagen Provides Regulatory Update Following Productive
GlobeNewswire ·
- Vistagen Therapeutics, Inc. expected to post a loss of 37 cents a share - Earnings Preview
TradingView ·
- VTGN Q2'26 Earnings: EPS estimate is (0.38) USD
TradingView ·
- Vistagen Selects GATC Health to Apply Predictive AI Across Lead Clinical-Stage Drug Development Programs
Yahoo Finance ·
- Vasomotor Symptoms Market Poised for Growth Through 2036, Driven by Rising Adoption of Hormonal and Non-Hormonal Therapies | DelveInsight
Yahoo Finance ·
- 2 Falling Stocks Call Traders Are Targeting Today
Yahoo Finance ·
Vistagen Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | – | – | – | -$227,000 |
| Net income | -$69.7M | -$51.4M | -$29.4M | -$59.2M |
| Diluted EPS | $-1.83 | $-1.67 | $-1.52 | $-8.51 |
| Total assets (year end) | $65.1M | $92.3M | $131.1M | $29.7M |
| Cash and equivalents (year end) | $47.4M | $74.7M | $126.6M | $25.0M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Vistagen Therapeutics, Inc.
- Ticker
- VTGN (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- South San Francisco, CA
- Incorporated in
- NV
- Fiscal year end
- March 31
- SEC CIK
- 1411685
- Former names
- Excaliber Enterprises, Ltd.
Frequently asked questions
What exchange is Vistagen Therapeutics, Inc. listed on?
Vistagen Therapeutics, Inc. trades on the Nasdaq under the ticker symbol VTGN.
What industry is Vistagen Therapeutics, Inc. in?
Vistagen Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Vistagen Therapeutics, Inc. headquartered?
Vistagen Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Vistagen Therapeutics, Inc.'s fiscal year end?
Vistagen Therapeutics, Inc.'s fiscal year ends on March 31.
How much revenue did Vistagen Therapeutics, Inc. report?
Vistagen Therapeutics, Inc. reported -$227,000 in revenue for calendar year 2022, according to its SEC filings.